Quarterly Updates14 Nov 2025, 06:02 pm
Kilitch Drugs' PAT Rises by 18% YoY to ₹10.30 Crore in H1 FY26
AI Summary
Kilitch Drugs Limited, a leading pharmaceutical company, announced its unaudited financial results for the half year ended September 30, 2025. The company reported a Profit After Tax of ₹10.30 crore in H1 FY26, an 18.1% increase compared to ₹8.72 crore in H1 FY25. Total income for the period stood at ₹101.28 crore, registering a 14.23% YoY growth from ₹88.66 crore in H1 FY25. The company continues to strengthen its presence in domestic and international markets, driven by sustained orders for its parenteral range and increasing traction in oral solids and effervescent formulations.
Key Highlights
- Profit After Tax (PAT) increased by 18.1% YoY to ₹10.30 crore in H1 FY26
- Total income grew by 14.23% YoY to ₹101.28 crore in H1 FY26
- Improved operational efficiencies, better product mix and consistent demand across key markets supported the growth in profitability
- Strengthening presence in domestic and international markets
- Sustained orders for parenteral range and increasing traction in oral solids and effervescent formulations
- Successfully completed a rights issue of ₹4992.51 lakh to fund the capital expenditure for its upcoming Greenfield Project at Pen